In a new Analytical Cannabis webinar held on March 8, Eric Janusson, lead chemist at the Vancouver-based Delic Labs, will present new methods being developed by Delic to produce accurate results for psilocybin quantitation. Here's what he had to say ahead of that webinar.
After giving the drugs to participants and reviewing their experiences, the researchers concluded that both doses of LSD and the higher dose of psilocybin produced comparable psychedelic effects.
Given the rising popularity of microdosing, the researchers say that more scientific study into the practice is urgently needed.
Almost all participants reported feeling significantly less depressed when they met up with the researchers a week after treatment, and most continued to report lower depression scores 3 months, 6 months, and 12 months after their psilocybin trip.
While the DEA says that these drugs all “have a high potential for abuse,” advocates argue that the new rule could lead to more harm than good.
Patients hospitalized for severe suicidal ideation could benefit from ketamine transfusions, according to new research led by scientists at the University of Montpellier.
Trevor James Hamilton, an associate professor in neuroscience at MacEwan University, discusses his research into how LSD affects zebrafish – and the implications it could have for mental health treatment.
The field of psychedelic drug research is experiencing a renaissance. But this could come at a cost of scientific integrity, argue some researchers.
Researchers have found potentially non-hallucinatory psychedelic compounds by examining crystal structures.
Research from Alex Kwan’s lab has suggested that dendritic plasticity may help support the idea that ketamine and psilocybin can help individuals adopt new perspectives and better process new experiences.